Genelux Investor Presentation Deck

Diversified Designs and Indications Exploit Competitive Advantages Olvi-Vec Regional Route Systemic Route V2ACT Immunotherapy Systemic Route V-VET1 Systemic Route GENELUX Human Health Ovarian Cancer (platinum-resistant/refractory) Non-Small Cell Lung Cancer (Adjuvant Maintenance) Small Cell Lung Cancer (recurrent) Ovarian Cancer (recurrent) Non-Small Cell Lung Cancer (relapsed/recurrent) Pancreatic Cancer Animal Health Hematologic and solid tumors Design Olvi-Vec (i.pe) + Chemotherapy Olvi-Vec (IV) + Chemotherapy Olvi-Vec (IV) + Chemotherapy Olvi-Vec (IV) + Chemotherapy Olvi-Vec (IV) + Chemotherapy Olvi-Vec (IV) + Adoptive Cell Therapy V-VET1 (IV) +/- standard of care Preclinical Phase 2 Regulatory Submission Ph1b/2 enrolling Ph1b/2 Regulatory Submission Planned Preclinical Regulatory Submission Phase 1 Ph3 OnPrime/GOG-3076 Study Actively Enrolling Safety Preparing Phase 1 Phase 2 Preliminary Efficacy Phase 3 Phase 2 Phase 3 Pivotal Efficacy Collaborators GOG (Cooperative Group) FOUNDATION" Transforming the standard of care NEWSOARA 恒翼生物医药 (Greater China) VACT THERAPEUTICS (Worldwide Rights Ex-Greater China) ELIAS ANIMAL HEALTH (Worldwide) 5

View entire presentation